Similar companies
Income Statement (USD)
| Q1 '25 | QoQ | |
|---|---|---|
| Revenue | 2.7M | 102.2% |
| Gross Profit | 2.5M | 102.4% |
| Cost of Revenue | 250,000 | 101.2% |
| Operating expense | 17M | 258% |
| Net Income | -17M | 193.2% |
| EBITDA | -15M | 83.6% |
Balance Sheet (USD)
| Q1 '25 | QoQ | |
|---|---|---|
| Total Assets | 165M | 23% |
| Total Liabilities | 340M | 14.6% |
| Shares Outstanding | 101M | 0.1% |
Cash Flow (USD)
| Q1 '25 | QoQ | |
|---|---|---|
| Cash from operations | 2.7M | 108.9% |
| Cash from financing | -88,000 | 1860% |
EPS
Financial Highlights for FibroGen in Q1 '25
FibroGen reported a revenue of 2.7M, which is a 102.2% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at 2.5M, marking a 102.4% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 250,000, a 101.2% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 17M, showing a 258% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -17M, showing a -193.2% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was -15M, showing a 83.6% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
FibroGen faced some challenges this quarter with a decline in one or more of the key metrics: revenue, gross profit, or net income. Higher operating expenses might indicate increased investments or potential inefficiencies.
